PubliczneCentraOnkologii.pl: What is AIMPN disease; as often occurs and how it is diagnosed? prof.

Home> Uncategorized> Conflict HIV and alloimmune thrombocytopenia fetuses and newborns (AIMP / N) - interview with prof. Conflict Brojer Eve serological and allo thrombocytopenia in fetuses and neonates (AIMP / N) - interview with prof. Eve Brojer
PubliczneCentraOnkologii.pl: Institute of Hematology and Blood Transfusion researching dermatologist alloimmune thrombocytopenia fetuses and newborns (AIMPN) dermatologist in Poland, which is AIMPN and what is it about the study? prof. Assoc. n. med. Ewa Brojer: alloimmune thrombocytopenia research on fetuses dermatologist and newborns (AIMPN) are conducted by the Department of Immunology and Hematology Transfuzjologicznej Institute of Haematology and Transfusion (IHiT) together with the University of Tromso (Norway), under a grant from the Programme by the Polish -Norweskkiej Research Cooperation, conducted by the National Research and Development Centre of the Norwegian Financial Mechanism 2009-2014. Grant is dedicated to maternal-płodowemu conflict in terms of HPA-1a antigen dermatologist plates, which may be a consequence of this dangerous disease of the fetus or newborn. University of Tromso, like the Department of Immunology has many years of experience of working on platelet conflicts. Our team conducted this research since the 80's. Led them to Professor Barbara Żupańska, which is now retired. The grant team work while her closest collaborators dermatologist - Professor. Krystyna Buttermilk, Dr. Malgorzata Uhrynowska and Dr. Catherine tumor. From the gynecological and obstetric work from the beginning of prof. Romuald Dębski and Dr. Marzena Dębska of the Department of Obstetrics and Gynecology at the hospital Bielański dermatologist CMKP. The fact that the two teams - Norwegian and Polish have years of experience in the development of AIMPN will be important to achieve this prestigious grant. Returning to AIMPN. AIMPN is the result of a conflict of maternal -płodowego on platelets. Platelet conflict is somewhat analogous to the well-known Rh (this leads to anemia - hemolytic disease of the fetus / newborn - because the antibodies are directed to the red blood cells). Platelet conflict, in contrast to the conflict for red cell antigens may occur in the first pregnancy. The conflict in the antigens HPA-1 (from the Human Platelet Antigens dermatologist called), we are dealing with is the most common (more than 85% of conflict concerns the antigen) and heaviest in terms of clinical implications, conflict plate.
The aim of the project dermatologist is to develop and implement dermatologist methods of identifying women who do not have HPA1a antigen (HPA-1BB are - that HPA1a negative) and are at risk of the development of antibodies dermatologist to the antigen if the fetus had inherited it from his father. In these women will do diagnostic tests: appearance and concentration of anti HPA-1a and non-invasive test for the presence of fetal antigen HPA1a based on the analysis of fetal DNA in maternal plasma. Women with antibodies will be treated. In women HPA1bb will analyze known and probable biomarkers, to anticipate production of antibodies by the mother and the occurrence of thrombocytopenia in the fetus / child. Our observations allow us to standardize the diagnosis and management of women at risk of conflict in the HPA-1a. An important result of the project will be the creation of a biobank samples analyzed women. The collected samples will be used for future analysis of cellular mechanisms of the immune response in women with conflict HPA-1a.
PubliczneCentraOnkologii.pl: What is AIMPN disease; as often occurs and how it is diagnosed? prof. Assoc. n. med. Ewa Brojer: AIMPN prevalence of 1/1000 - 2000 live births. Its clinical course varies from petechiae and stroke occurrence, including intracranial hemorrhage leading dermatologist to fetal death or severe neurological sequelae such as mental retardation, cerebral palsy, dermatologist cortical blindness, seizures. The incidence of CNS hemorrhage caused AIMPN estimated at approx. 1:12 500. The nozzle of a full-term, well-developing disease of the newborn is often quite unexpected - a healthy mother runs properly pregnancy and gives birth to a child with spout. The nozzle can be attributed to errors in prowadzniu birth, and low platelet interpreted as a consequence, not a cause of stroke. In about 1/3 of the cases, despite the existence of a conflict and the presence of antibodies child has no clinical symptoms. AIMPN is a self-limiting disease - although the number of platelet-born child could fall even after the birth for a few days - normalization of platelet counts in untreated children most often occurs within a few days. It is important, however, that women who have experienced conflict fetal platelet dermatologist disease generally repeated in a subsequent pregnancy, unless another child does not inherit from the father dermatologist of the antigen, which